(Press-News.org) WASHINGTON (March 30, 2014) — Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable to take statins, according to research from GAUSS-2 presented at the American College of Cardiology's 63rd Annual Scientific Session.
High LDL cholesterol is considered a major risk factor for cardiovascular disease. Statins are commonly prescribed to reduce that risk. Currently ezetimibe is one of the few options to lower LDL-C for patients who cannot tolerate statins, but it is less effective than statins in decreasing LDL-C.
GAUSS-2 is a 14-country, 12-week double-blind comparison of subcutaneously administered evolocumab versus oral ezetimibe in patients with high cholesterol who were unable to tolerate effective doses of at least two different statins. In this phase III study, half of patients tried three statins unsuccessfully, and 22 percent couldn't tolerate any of at least four different statin drugs. The patients had a minimum LDL-C level of 193 mg/dL.
A total of 307 patients were randomly assigned to one of two evolocumab regimens (140 mg every two weeks or 420 mg per month, plus daily placebo) or one of two ezetimibe groups (a placebo injection every two weeks or monthly, plus 10 mg oral ezetimibe daily). Mean age was 62 years, and 46 percent of patients were women.
The primary endpoints of LDL-C reductions from baseline were met: 53 percent to 56 percent decrease of LDL-C from baseline at week 12 in evolocumab-treated patients, corresponding to a 37 percent to 39 percent LDL-C decrease with ezetimibe. Musculoskeletal side effects were reported in 12 percent of patients on evolocumab compared to 23 percent on ezetimibe. More than 94 percent of all enrolled patients completed the study. The study drug was stopped because of treatment-related side effects in 8 percent of evolocumab patients and 13 percent of ezetimibe patients. Safety data for evolcumab versus ezetimibe include the following side effects: headache (8 percent vs. 9 percent), muscle pain (8 percent vs. 18 percent), pain in extremities (7 percent vs. 1 percent), muscle spasms (6 percent vs. 4 percent), fatigue (4 percent vs. 10 percent), nausea (4 percent vs. 7 percent), diarrhea (2 percent vs. 7 percent), sensation of tingling, prickling or burning known as paresthesia (1 percent vs. 5 percent). Patients who were taking low-dose statins were more likely to develop muscle pain in both study arms than those who took no statins (evolocumab, 17 percent vs. 6 percent; ezetimibe, 21 percent vs. 17 percent).
"We have a growing population of patients treated with at least two different types of statins who still experience side effects so much they want to discontinue the drug," said Erik S.G. Stroes, M.D., chair and professor at the Department of Vascular Medicine in Amsterdam's Medical Center and the study's principal investigator. "The one big difference between our study and others in patients at increased cardiovascular risk is that for these patients, we don't have a good alternative treatment – no drug with robust LDL-lowering potency and good tolerability. For clinicians trained to solve problems, an unmet clinical need is a big issue."
Earlier studies indicate that more than 75 percent of patients who failed one statin can still do well on a second statin drug. This finding makes patients who have been unable to tolerate two or more statins a particularly challenging group.
Stroes noted that clinicians have debated whether cardiovascular patients would accept a drug administered by injection, but the study's cardiovascular physicians and internists found few problems with the subcutaneous regimen. Evolocumab must be delivered by this route because it's a fully human monoclonal antibody, a protein that will be broken down in the stomach and bowel if taken orally.
"What's innovative here is that if you give a drug, it's hardly ever specific; statins, for example, can work on a lot of organs," Stroes said. "An antibody is, in and of itself, inert. It binds selectively to a particular sequence on a protein or bacteria and can have a predictable effect on a particular system. That's most likely why evolocumab has a good safety profile with very high efficacy. This study suggests that statin-induced myopathy [muscle discomfort] may be due to another molecular pathway and is not related to LDL-C lowering per se."
There is no generally accepted definition of statin intolerance yet, Stroes said. The GAUSS-3 study, planned to start in the second half of 2014, will include a separate placebo-controlled re-exposure to statin before evolocumab therapy.
"It will help in further delineating statin intolerance and how that should be defined in clinical practice," he said.
Stroes noted two limitations to the study. Reducing LDL-C levels has been demonstrated to translate into a reduced risk of cardiovascular events primarily with statin treatment. The benefit of evolocumab on cardiovascular endpoints awaits the results of the ongoing FOURIER trial. Additionally, the 12-week duration of this study was rather short considering that the majority of patients require life-long treatment to manage LDL-C. The good tolerability observed in this study also needs confirmation in the ongoing long-term trials, Stroes said.
INFORMATION:
The GAUSS-2 trial was funded by Amgen, Inc.
This study will be simultaneously published online in the Journal of the American College of Cardiology at the time of presentation.
Evolocumab superior to ezetimibe in lowering LDL cholesterol
Investigational anti-PCSK9 drug effective for clinically challenging statin-intolerant patients
2014-03-31
ELSE PRESS RELEASES FROM THIS DATE:
Head-to-head study favors balloon-expandable transcatheter heart valves
2014-03-31
WASHINGTON (March 30, 2014) — A first-ever randomized head-to-head comparison of two devices commonly used to treat the age-related disease aortic stenosis finds balloon-expandable transcatheter valves result in more successful procedures and relieve symptoms more frequently than self-expanding valves, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
Aortic stenosis is a condition in which a crucial valve in the heart ceases to function properly. The only cure is to replace the valve, either through open heart surgery ...
Higher risks without cardio benefits halt study of aleglitazar
2014-03-31
WASHINGTON (March 30, 2014) — The phase III AleCardio trial was ended early when patients with type 2 diabetes and recent acute coronary syndrome who were treated with aleglitazar showed higher rates of heart failure, kidney events and gastrointestinal bleeding with no offsetting cardiovascular benefits, according to data presented at the American College of Cardiology's 63rd Annual Scientific Session. All other studies with the drug have been stopped as well.
Aleglitazar sparked interest for this patient population because of its dual action on two subtypes of the PPAR ...
Darapladib falls short in chronic coronary heart disease
2014-03-31
WASHINGTON (March 30, 2014) — The novel inflammation inhibitor darapladib showed no primary-endpoint advantage over placebo in patients with chronic coronary heart disease treated with a high level of background care, although it did suggest possible benefits for more specific coronary artery-related endpoints, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. STABILITY is the first study to test this inflammation-prevention mechanism for reducing the likelihood that plaque will become an artery-blocking clot.
Darapladib ...
Evolocumab safely drops LDL cholesterol well below statin-only baseline
2014-03-31
WASHINGTON (March 30, 2014) — The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 study presented at the American College of Cardiology's 63rd Annual Scientific Session.
LDL cholesterol is considered a major risk factor for cardiovascular disease. "High-risk patients – such as those with clinical cardiovascular disease, high LDL cholesterol levels or diabetes – are ideally treated with high-intensity ...
Anti-gout medication colchicine helps patients with recurrent pericarditis
2014-03-31
WASHINGTON (March 30, 2014) — A medication traditionally used to treat gout is also effective at treating recurrent pericarditis, an inflammation of the sac-like covering around the heart, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
In the first multicenter, double-blind trial to look at the use of colchicine for multiple recurrences of pericarditis, 240 patients were randomly assigned to either the study drug or placebo to examine the primary endpoint of recurrent pericarditis. The rate of disease recurrence ...
Renal denervation patient registry finds low rate of adverse events
2014-03-31
WASHINGTON (March 30, 2014) — Patients with uncontrolled high blood pressure treated with renal denervation had low rates of adverse events and significant lowering of blood pressure at six months, according to a registry-based study presented at the American College of Cardiology's 63rd Annual Scientific Session.
The Global SYMPLICITY Registry is the first and largest dataset of patients with uncontrolled hypertension treated with renal denervation. The open-label, multicenter study was established to examine the safety and effectiveness of the procedure. Outcomes presented ...
Post-approval study of transcatheter pulmonary valve completes 1 year
2014-03-31
WASHINGTON (March 30, 2014) — The first post-FDA approval study of a non-surgically implanted replacement pulmonary valve showed strong short- and mid-term results for the device in a small sample of patients with certain congenital heart defects, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
This multi-center study of 100 patients consecutively implanted with the Melody transcatheter pulmonary valve between July 2010 and July 2012 assessed the effectiveness of the device at six and 12 months based on the percentage ...
Cardiac resynchronization improves survival in heart failure patients
2014-03-31
WASHINGTON (March 30, 2014) — Patients in mild heart failure who receive a specialized pacemaker known as cardiac resynchronization therapy with a defibrillator (CRT-D) may live longer than those implanted with a traditional implantable cardioverter defibrillator (ICD), according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
In the first study to look at CRT-D in mildly symptomatic patients, researchers found that patients with left bundle branch block implanted with a CRT-D had a 41 percent reduced risk of death compared ...
Blood test helps predict heart attack risk for patients with chest pain
2014-03-31
WASHINGTON (March 30, 2014) — Patients presenting to the emergency department with an undetectable level of the blood biomarker high-sensitivity cardiac troponin T, and whose ECGs show no sign of restricted blood flow, have a minimal risk of heart attack within 30 days, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
In a study of all patients (14,636 in total) reporting to a Swedish emergency department with chest pain over a two-year period from 2010 to 2012, researchers examined patients' blood levels of high-sensitivity ...
The Atlantic Ocean dances with the sun and volcanoes
2014-03-31
Imagine a ballroom in which two dancers apparently keep in time to their own individual rhythm. The two partners suddenly find themselves moving to the same rhythm and, after a closer look, it is clear to see which one is leading.
It was an image like this that researchers at Aarhus University were able to see when they compared studies of solar energy release and volcanic activity during the last 450 years, with reconstructions of ocean temperature fluctuations during the same period.
The results actually showed that during the last approximately 250 years – since ...
LAST 30 PRESS RELEASES:
UTokyo and NARO develop new vertical seed distribution trait for soybean breeding
Research into UK’s use of plastic packaging finds households ‘wishcycle’ rather than recycle – risking vast contamination
Vaccine shows promise against aggressive breast cancer
Adverse events affect over 1 in 3 surgery patients, US study finds
Outsourcing adult social care has contributed to England’s care crisis, argue experts
The Lancet: Over 800 million adults living with diabetes, more than half not receiving treatment, global study suggests
New therapeutic approach for severe COVID-19: faster recovery and reduction in mortality
Plugged wells and reduced injection lower induced earthquake rates in Oklahoma
Yin selected as a 2024 American Society of Agronomy Fellow
Long Covid could cost the economy billions every year
Bluetooth technology unlocks urban animal secrets
This nifty AI tool helps neurosurgeons find sneaky cancer cells
Treatment advances, predictive biomarkers stand to improve bladder cancer care
NYC's ride-hailing fee failed to ease Manhattan traffic, new NYU Tandon study reveals
Meteorite contains evidence of liquid water on Mars 742 million years ago
Self-reported screening helped reduce distressing symptoms for pediatric patients with cancer
Which risk factors are linked to having a severe stroke?
Opening borders for workers: Abe’s profound influence on Japan’s immigration regime
How skills from hospitality and tourism can propel careers beyond the industry
Research shows managers of firms handling recalls should review media scrutiny before deciding whether to lobby
New model system for the development of potential active substances used in condensate modifying drugs
How to reduce social media stress by leaning in instead of logging off
Pioneering research shows sea life will struggle to survive future global warming
In 10 seconds, an AI model detects cancerous brain tumor often missed during surgery
Burden of RSV–associated hospitalizations in US adults, October 2016 to September 2023
Repurposing semaglutide and liraglutide for alcohol use disorder
IPK-led research team provides insights into the pangenome of barley
New route to fluorochemicals: fluorspar activated in water under mild conditions
Microbial load can influence disease associations
Three galactic “red monsters” in the early Universe
[Press-News.org] Evolocumab superior to ezetimibe in lowering LDL cholesterolInvestigational anti-PCSK9 drug effective for clinically challenging statin-intolerant patients